^
    Back
    Association details:
    Biomarker:FLT3 D835
    Cancer:Acute Myelogenous Leukemia
    Drug:crenolanib (ARO-002) (FLT3 inhibitor, PDGFR α inhibitor, PDGFR β inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Crenolanib Maintenance Following Allogeneic Stem Cell Transplantation in FLT3-positive Acute Myeloid Leukemia Patients

    Excerpt:
    ...FLT3-ITD or FLT3-D835 positive disease at any time during disease course....
    Trial ID:
    NCT02400255
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Study Investigating the Efficacy of Crenolanib With Chemotherapy vs Chemotherapy Alone in R/R FLT3 Mutated AML

    Excerpt:
    ...Presence of FLT3-ITD and/or D835 mutation(s) 3....
    Trial ID:
    NCT03250338
    More C2 evidence
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    A Study of Crenolanib With Fludarabine and Cytarabine in Pediatric Patients With Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia

    Excerpt:
    ...Definitive evidence of a FLT3-ITD and/or FLT3-TKD (D835/I836) mutation at the time of enrollment 4....
    Trial ID:
    NCT03324243
    Less C2 evidence
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    J Hematol Oncol
    Title:

    Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML

    Published date:
    10/08/2020
    Excerpt:
    A total of 239 patients with FLT3-ITD- and/or FLT3-D835-mutated AML who received FLT3i-based treatments (including single-agent or combination FLT3i therapies) were identified...Of the 21 patients harboring D835 TKD mutations, 6 achieved CRc (30%): 14 received crenolanib (4 achieved CRc), 3 quizartinib (1 CRc), 2 gilteritinib (1 CRc), and 2 sorafenib (no CRc) as first FLT3i.
    DOI:
    10.1186/s13045-020-00964-5